10x Genomics, Fred Hutch launch clinical research collaboration on single-cell, spatial oncology applications
Bitget2026/10/07 13:0210x Genomics launched a clinical research collaboration with Fred Hutch to extend its oncology evidence base into blood cancers. Bladder cancer work will study whether single-cell and spatial readouts can predict treatment response, aiming to support future therapy selection. A separate acute myeloid leukemia project will test whether single-cell analysis can improve residual disease detection versus today’s fragmented approach. No clinical results were reported; findings are expected in future readouts as the studies progress. Effort supports groundwork for potential diagnostic use, including a clinical reporting framework tied to 10x’s planned CLIA-certified lab. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 10x Genomics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610070900PR_NEWS_USPR_____LA65153) on October 07, 2026, and is solely responsible for the information contained therein.
- 10x Genomics launched a clinical research collaboration with Fred Hutch to extend its oncology evidence base into blood cancers.
- Bladder cancer work will study whether single-cell and spatial readouts can predict treatment response, aiming to support future therapy selection.
- A separate acute myeloid leukemia project will test whether single-cell analysis can improve residual disease detection versus today’s fragmented approach.
- No clinical results were reported; findings are expected in future readouts as the studies progress.
- Effort supports groundwork for potential diagnostic use, including a clinical reporting framework tied to 10x’s planned CLIA-certified lab.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The AI arms race extends upstream! Reports say Intel, Nvidia, and AMD are prepaying over 100 billions NTD to secure advanced IC substrate production capacity.
NVIDIA, Intel, and AMD have collectively spent $5 billion in advance payments to aggressively secure high-end IC substrates from Taiwan. Driven by "big money for guaranteed orders," the top three Taiwanese substrate manufacturers have invested a record NT$161.2 billion to expand their production capacity. The tech giants' substantial financial commitments to secure supply chains highlight the intense competition and extreme scarcity of core AI materials.
Brent Crude Oil Hits $116 as Markets Weigh Another Inflation Shock
Crypto prices
More
